A Phase 2 interventional study of Donidalorsen in Hereditary Angioedema, sponsored by Ionis Pharmaceuticals, Inc.. Completed at 7 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-08.
Sponsored by Ionis Pharmaceuticals, Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 84 studies in Angioedemas, Hereditary with a site in United States — 12 open to participants now, 18 under way, 10 of them phase 3. Angioedemas, Hereditary · United States.
Among the 84 studies in Angioedemas, Hereditary with a site in United States, this one is the 61st largest by enrollment of the 74 interventional ones that give a count, is one of 2 that started in 2020, is one of 16 in phase 2, and was the 45th registered.
171 studies on the registry are indexed under Angioedemas, Hereditary; 24 are open to participants now.
Browse Angioedemas, Hereditary studies →12 of the 84 studies in Angioedemas, Hereditary with a site in United States are open now. Recruiting first, the newest first:
KalVista Pharmaceuticals, Ltd. · Sites in United States
Ages 12+
Ionis Pharmaceuticals, Inc. · Sites in United States, Australia, Italy and 2 more countries
Ages 2–11
ADARx Pharmaceuticals, Inc. · Sites in United States, Argentina, Australia and 16 more countries
Ages 18+
Pharvaris Netherlands B.V. · Sites in United States, Australia, Austria and 13 more countries
Ages 18+
National Institute of Allergy and Infectious Diseases (NIAID) · Sites in United States
Ages 18–75
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 13 Angioedemas, Hereditary studies recruiting now, 9 (69%) set no upper age limit and 4 (31%) stop at 75 or younger; 7 take children under 18; 1 takes healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
84 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 23 · Phase 3 42 · Phase 4 6
First in 2004; this study’s year is marked. 2 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 20 is below the median of 48 across 116 interventional studies indexed under Angioedemas, Hereditary.
Median enrollment 57 across the 74 interventional studies, 168 across the 7 observational. Of the 62 that completed or were terminated, 47 (76%) have results posted.
This tab as a report to print or save as PDF → With an account.
77 of 84 have an industry lead sponsor. The 10 most frequent:
Ionis Pharmaceuticals, Inc. is the lead sponsor of 118 studies on the registry; 10 are open to participants now.
Of its 49 completed or terminated interventional studies of FDA-regulated products, 22 (45%) have results posted.
Ionis Pharmaceuticals, Inc. has 6 studies filed under Angioedemas, Hereditary — fewer than ten, so there is no comparison to draw.
7 of the studies in Angioedemas, Hereditary with a site in United States that are under way reach primary completion within a year, 5 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06842823Phase 3Astria Therapeutics, Inc.A Study of Navenibart in Participants With Hereditary Angioedema | 2026-12 |
| NCT05392114Phase 3Ionis Pharmaceuticals, Inc.A Study to Assess the Long-Term Safety and Efficacy of Donidalorsen in the Prophylactic Treatment of Hereditary Angioedema (HAE) | 2026-12 |
| NCT05396105Phase 3Pharvaris Netherlands B.V.Extension Study of Oral PHA-022121 for Acute Treatment of Angioedema Attacks in Patients With Hereditary Angioedema | 2027-06 |
| NCT07266805Phase 3Pharvaris Netherlands B.V.Study of Oral Deucrictibant XR Tablet for Prophylaxis and Deucrictibant Soft Capsule for On-Demand Treatment of Angioedema Attacks in Adults With Acquired Angioedema Due to C1 Inhibitor Deficiency | 2027-06 |
| NCT06960213Phase 3ADARx Pharmaceuticals, Inc.STOP-HAE: A Phase 3 Study of ADX-324 in HAE | 2027-11-30 |
Add all 7 to your calendar (.ics) → With an account.
Among the 84 studies in Angioedemas, Hereditary with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study was to evaluate the safety and efficacy of extended dosing of donidalorsen administered subcutaneously (SC), with alternative dosing and/or dose frequency with donidalorsen in participants with hereditary angioedema (HAE).
This was an open-label extension study of donidalorsen in 20 participants with HAE. The length of participation in the study was approximately 68 weeks, which included an up to 4-week qualification period, a 52-week treatment period, and a 12-week post-treatment period. Following the Week 53 treatment period visit, participants received donidalorsen in an extended treatment period for up to an additional 156 weeks. Participants taking part in the extended treatment period entered the 12-week post-treatment period after completion of, or early termination from, the extended treatment period.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
1. Have any new condition or worsening of an existing condition or change or anticipated change in medication, which in the opinion of the Investigator would make the participant unsuitable for enrollment, or could interfere with the participant participating in or completing the study
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with hereditary angioedema Type I/Type II (HAE-1/HAE-2) who received placebo or donidalorsen, 80 milligrams (mg), SC once every 4 weeks, in the previous study ISIS 721744-CS2 (NCT04030598), received donidalorsen, 80 mg, SC once every 4 weeks, from Week 1 to Week 13 (Fixed Dosing Period). Starting From Week 17 (Flexible Dosing Period), participants had 3 different dosing options as: 80 mg every 4 weeks, 80 mg every 8 weeks for participants who were attack-free for ≥12 weeks, 100 mg every 4 weeks for participants who were not attack-free for ≥12 weeks up to Week 53 based on the investigator and sponsor medical monitor recommendation. Participants continued flexible dosing from Week 53 for up to approximately 209 weeks.
Drug: Donidalorsen
Participants with hereditary angioedema with normal C1-inhibitor (HAE-nC1-INH) who received donidalorsen, 80 mg, SC, once every 4 weeks, in the previous study ISIS 721744-CS2 (NCT04030598), continued to receive donidalorsen, 80 mg, SC once every 4 weeks, from Week 1 to Week 13 (Fixed Dosing Period). Starting From Week 17 (Flexible Dosing Period), participants had 2 different dosing options as: 80 mg every 4 weeks, and 100 mg every 4 weeks for participants who were not attack-free for ≥12 weeks up to Week 53 based on the investigator and sponsor medical monitor recommendation. Participants continued flexible dosing from Week 53 for up to approximately 209 weeks.
Drug: Donidalorsen
Donidalorsen administered SC
Also known as: ISIS 721744, IONIS-PKK-LRx
Percentage of Participants With Treatment-emergent Adverse Events (TEAEs)
An adverse event (AE) was defined as any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not the AE is considered related to the medicinal (investigational) product. TEAEs were defined as those AEs that either started or worsened in severity on or after the date/time of first administration of study drug in this OLE Study. TEAEs included both serious and non-serious TEAEs.
Time frame: Up to Week 221
Percentage of Participants With Clinically Meaningful Changes in Clinical Laboratory Assessments
Clinical laboratory tests including clinical chemistry, hematology, coagulation, complement, inflammatory, urinalysis were performed. The percentage of participants with clinically meaningful changes were reported. Clinical meaningfulness was determined by the investigator.
Time frame: Up to Week 221
Percentage of Participants With Clinically Meaningful Changes in Vital Signs
Vital sign measurements including heart rate, respiratory rate, body temperature, systolic and diastolic blood pressure and pulse pressure were assessed. Percentage of participants with clinically meaningful changes in the vital signs were reported. Clinically meaningfulness was determined by the investigator.
Time frame: Up to Week 221
Percentage of Participants With Clinically Meaningful Changes in Electrocardiograms (ECGs) Parameters
The ECG parameters included ventricular rate, PR interval, QRS duration, QTc, QT corrected using the Fridericia's formula (QTcF), QT corrected using the Bazett's formula (QTcB), and overall interpretation. Percentage of participants with clinically meaningful changes in the ECG parameters were reported. Clinical meaningfulness was determined by the investigator.
Time frame: Up to Week 221
Percentage of Participants Who Received At Least One Concomitant Medication
Concomitant medications include medications that participants were exposed to on or after the first dose of ISIS 721744 in the OLE study. Percentage of participants who received at least one concomitant medication were reported.
Time frame: Up to Week 221
Percent Change From Baseline in Time-normalized HAE Attack (Per 4 Weeks) Rate
HAE attack rate was calculated for each participant as the number of HAE attacks occurring during the respective period divided by the number of days the participant contributed to this period multiplied by 28 days. An HAE attack was defined as an event with signs or symptoms consistent with an attack in at least 1 of the locations: peripheral angioedema (cutaneous swelling involving an extremity, the face, neck, torso, and/or genitourinary region), abdominal angioedema (abdominal pain, with or without abdominal distention, nausea, vomiting, or diarrhea), laryngeal angioedema (stridor, dyspnea, difficulty speaking, difficulty swallowing, throat tightening, or swelling of the tongue, palate, uvula, or larynx). A negative change from baseline in HAE attacks indicates an improvement in HAE attacks.
Time frame: Up to Week 221
Percentage of Participants Who Used On-demand Medications
The most commonly used on-demand medications during the On-Treatment Period were C1 esterase inhibitors (human) and icatibant, which were allowed per-protocol for treatment of acute attacks.
Time frame: Up to Week 221
Participants took part in the study from 31 March 2020 to 24 January 2025.
| Milestone | HAE-1/HAE-2 | HAE-nC1-INH |
|---|---|---|
| Started | 17 | 3 |
| Flexible-dose period: hae-1/hae-2 (donidalorsen 80 mg every 4 weeks) | 13 | 0 |
| Flexible-dose period: hae-1/hae-2 (donidalorsen 80 mg every 8 weeks) | 8 | 0 |
| Flexible-dose period: hae-1/hae-2 (donidalorsen 100 mg every 4 weeks) | 1 | 0 |
| Flexible-dose period: hae-nc1-inh (donidalorsen 80 mg every 4 weeks) | 0 | 1 |
| Flexible-dose period: hae-nc1-inh (donidalorsen 100 mg every 4 weeks) | 0 | 2 |
| Completed | 16 | 2 |
| Not completed | 1 | 1 |
| Withdrew: Voluntary withdrawal | 1 | 1 |
An adverse event (AE) was defined as any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not the AE is considered related to the medicinal (investigational) product. TEAEs were defined as those AEs that either started or worsened in severity on or after the date/time of first administration of study drug in this OLE Study. TEAEs included both serious and non-serious TEAEs.
| percentage of participants | Fixed-dose Period: HAE-1/HAE-2 | Fixed-dose Period: HAE-nC1-INH | Flexible-dose Period: HAE-1/HAE-2 (Donidalorsen 80 mg Every 4 Weeks) | Flexible-dose Period: HAE-1/HAE-2 (Donidalorsen 80 mg Every 8 Weeks) | Flexible-dose Period: HAE-1/HAE-2 (Donidalorsen 100 mg Every 4 Weeks) | Flexible-dose Period: HAE-nC1-INH (Donidalorsen 80 mg Every 4 Weeks) | Flexible-dose Period: HAE-nC1-INH (Donidalorsen 100 mg Every 4 Weeks) |
|---|---|---|---|---|---|---|---|
| Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) | 70.6 | 66.7 | 84.6 | 62.5 | 100 | 100 | 100 |
Clinical laboratory tests including clinical chemistry, hematology, coagulation, complement, inflammatory, urinalysis were performed. The percentage of participants with clinically meaningful changes were reported. Clinical meaningfulness was determined by the investigator.
| percentage of participants | Fixed-dose Period: HAE-1/HAE-2 | Fixed-dose Period: HAE-nC1-INH | Flexible-dose Period: HAE-1/HAE-2 (Donidalorsen 80 mg Every 4 Weeks) | Flexible-dose Period: HAE-1/HAE-2 (Donidalorsen 80 mg Every 8 Weeks) | Flexible-dose Period: HAE-1/HAE-2 (Donidalorsen 100 mg Every 4 Weeks) | Flexible-dose Period: HAE-nC1-INH (Donidalorsen 80 mg Every 4 Weeks) | Flexible-dose Period: HAE-nC1-INH (Donidalorsen 100 mg Every 4 Weeks) |
|---|---|---|---|---|---|---|---|
| Percentage of Participants With Clinically Meaningful Changes in Clinical Laboratory Assessments | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Vital sign measurements including heart rate, respiratory rate, body temperature, systolic and diastolic blood pressure and pulse pressure were assessed. Percentage of participants with clinically meaningful changes in the vital signs were reported. Clinically meaningfulness was determined by the investigator.
| percentage of participants | Fixed-dose Period: HAE-1/HAE-2 | Fixed-dose Period: HAE-nC1-INH | Flexible-dose Period: HAE-1/HAE-2 (Donidalorsen 80 mg Every 4 Weeks) | Flexible-dose Period: HAE-1/HAE-2 (Donidalorsen 80 mg Every 8 Weeks) | Flexible-dose Period: HAE-1/HAE-2 (Donidalorsen 100 mg Every 4 Weeks) | Flexible-dose Period: HAE-nC1-INH (Donidalorsen 80 mg Every 4 Weeks) | Flexible-dose Period: HAE-nC1-INH (Donidalorsen 100 mg Every 4 Weeks) |
|---|---|---|---|---|---|---|---|
| Percentage of Participants With Clinically Meaningful Changes in Vital Signs | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
The ECG parameters included ventricular rate, PR interval, QRS duration, QTc, QT corrected using the Fridericia's formula (QTcF), QT corrected using the Bazett's formula (QTcB), and overall interpretation. Percentage of participants with clinically meaningful changes in the ECG parameters were reported. Clinical meaningfulness was determined by the investigator.
| percentage of participants | Fixed-dose Period: HAE-1/HAE-2 | Fixed-dose Period: HAE-nC1-INH | Flexible-dose Period: HAE-1/HAE-2 (Donidalorsen 80 mg Every 4 Weeks) | Flexible-dose Period: HAE-1/HAE-2 (Donidalorsen 80 mg Every 8 Weeks) | Flexible-dose Period: HAE-1/HAE-2 (Donidalorsen 100 mg Every 4 Weeks) | Flexible-dose Period: HAE-nC1-INH (Donidalorsen 80 mg Every 4 Weeks) | Flexible-dose Period: HAE-nC1-INH (Donidalorsen 100 mg Every 4 Weeks) |
|---|---|---|---|---|---|---|---|
| Percentage of Participants With Clinically Meaningful Changes in Electrocardiograms (ECGs) Parameters | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Concomitant medications include medications that participants were exposed to on or after the first dose of ISIS 721744 in the OLE study. Percentage of participants who received at least one concomitant medication were reported.
| percentage of participants | HAE-1/HAE-2 | HAE-nC1-INH |
|---|---|---|
| Percentage of Participants Who Received At Least One Concomitant Medication | 100 | 100 |
HAE attack rate was calculated for each participant as the number of HAE attacks occurring during the respective period divided by the number of days the participant contributed to this period multiplied by 28 days. An HAE attack was defined as an event with signs or symptoms consistent with an attack in at least 1 of the locations: peripheral angioedema (cutaneous swelling involving an extremity, the face, neck, torso, and/or genitourinary region), abdominal angioedema (abdominal pain, with or without abdominal distention, nausea, vomiting, or diarrhea), laryngeal angioedema (stridor, dyspnea, difficulty speaking, difficulty swallowing, throat tightening, or swelling of the tongue, palate, uvula, or larynx). A negative change from baseline in HAE attacks indicates an improvement in HAE attacks.
| percent change | Fixed-dose Period: HAE-1/HAE-2 | Fixed-dose Period: HAE-nC1-INH | Flexible-dose Period: HAE-1/HAE-2 (Donidalorsen 80 mg Every 4 Weeks) | Flexible-dose Period: HAE-1/HAE-2 (Donidalorsen 80 mg Every 8 Weeks) | Flexible-dose Period: HAE-1/HAE-2 (Donidalorsen 100 mg Every 4 Weeks) | Flexible-dose Period: HAE-nC1-INH (Donidalorsen 80 mg Every 4 Weeks) | Flexible-dose Period: HAE-nC1-INH (Donidalorsen 100 mg Every 4 Weeks) |
|---|---|---|---|---|---|---|---|
| Percent Change From Baseline in Time-normalized HAE Attack (Per 4 Weeks) Rate | -94.41 ± 10.260 | -60.82 ± 19.310 | -97.21 ± 5.672 | -82.70 ± 35.598 | -95.16 ± NA | -87.21 ± NA | -64.04 ± 30.597 |
The most commonly used on-demand medications during the On-Treatment Period were C1 esterase inhibitors (human) and icatibant, which were allowed per-protocol for treatment of acute attacks.
| percentage of participants | Fixed-dose Period: HAE-1/HAE-2 | Fixed-dose Period: HAE-nC1-INH | Flexible-dose Period: HAE-1/HAE-2 (Donidalorsen 80 mg Every 4 Weeks) | Flexible-dose Period: HAE-1/HAE-2 (Donidalorsen 80 mg Every 8 Weeks) | Flexible-dose Period: HAE-1/HAE-2 (Donidalorsen 100 mg Every 4 Weeks) | Flexible-dose Period: HAE-nC1-INH (Donidalorsen 80 mg Every 4 Weeks) | Flexible-dose Period: HAE-nC1-INH (Donidalorsen 100 mg Every 4 Weeks) |
|---|---|---|---|---|---|---|---|
| By the End of Fixed Dosing Period (Week 17) | 11.8 | 66.7 | — | — | — | — | — |
| By the End of Flexible Dosing Period (Week 209) | — | — | 38.5 | 62.5 | 100 | 100 | 100 |
Collected over Up to Week 221. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Fixed-dose Period: HAE-1/HAE-2 | 0/17 (0%) | 0/17 (0%) | 12/17 (70.6%) |
| Fixed-dose Period: HAE-nC1-INH | 0/3 (0%) | 0/3 (0%) | 2/3 (66.7%) |
| Flexible-dose Period: HAE-1/HAE-2 (Donidalorsen 80 mg Every 4 Weeks) | 0/13 (0%) | 0/13 (0%) | 11/13 (84.6%) |
| Flexible-dose Period: HAE-1/HAE-2 (Donidalorsen 80 mg Every 8 Weeks) | 0/8 (0%) | 0/8 (0%) | 5/8 (62.5%) |
| Flexible-dose Period: HAE-1/HAE-2 (Donidalorsen 100 mg Every 4 Weeks) | 0/1 (0%) | 0/1 (0%) | 1/1 (100%) |
| Flexible-dose Period: HAE-nC1-INH (Donidalorsen 80 mg Every 4 Weeks) | 0/1 (0%) | 1/1 (100%) | 1/1 (100%) |
| Flexible-dose Period: HAE-nC1-INH (Donidalorsen 100 mg Every 4 Weeks) | 0/2 (0%) | 0/2 (0%) | 2/2 (100%) |
| Event | Fixed-dose Period: HAE-1/HAE-2 | Fixed-dose Period: HAE-nC1-INH | Flexible-dose Period: HAE-1/HAE-2 (Donidalorsen 80 mg Every 4 Weeks) | Flexible-dose Period: HAE-1/HAE-2 (Donidalorsen 80 mg Every 8 Weeks) | Flexible-dose Period: HAE-1/HAE-2 (Donidalorsen 100 mg Every 4 Weeks) | Flexible-dose Period: HAE-nC1-INH (Donidalorsen 80 mg Every 4 Weeks) | Flexible-dose Period: HAE-nC1-INH (Donidalorsen 100 mg Every 4 Weeks) |
|---|---|---|---|---|---|---|---|
| Abortion spontaneousPregnancy, puerperium and perinatal conditions | 0/17 | 0/3 | 0/13 | 0/8 | 0/1 | 1/1 | 0/2 |
| Event | Fixed-dose Period: HAE-1/HAE-2 | Fixed-dose Period: HAE-nC1-INH | Flexible-dose Period: HAE-1/HAE-2 (Donidalorsen 80 mg Every 4 Weeks) | Flexible-dose Period: HAE-1/HAE-2 (Donidalorsen 80 mg Every 8 Weeks) | Flexible-dose Period: HAE-1/HAE-2 (Donidalorsen 100 mg Every 4 Weeks) | Flexible-dose Period: HAE-nC1-INH (Donidalorsen 80 mg Every 4 Weeks) | Flexible-dose Period: HAE-nC1-INH (Donidalorsen 100 mg Every 4 Weeks) |
|---|---|---|---|---|---|---|---|
| COVID-19Infections and infestations | 2/17 | 0/3 | 5/13 | 3/8 | 0/1 | 1/1 | 1/2 |
| Urinary tract infectionInfections and infestations | 0/17 | 1/3 | 2/13 | 1/8 | 1/1 | 0/1 | 0/2 |
| AnxietyPsychiatric disorders | 0/17 | 0/3 | 2/13 | 0/8 | 0/1 | 1/1 | 1/2 |
| Emotional distressPsychiatric disorders | 0/17 | 0/3 | 0/13 | 0/8 | 0/1 | 1/1 | 0/2 |
| VomitingGastrointestinal disorders | 1/17 | 0/3 | 0/13 | 0/8 | 1/1 | 0/1 | 0/2 |
| Viral infectionInfections and infestations | 0/17 | 0/3 | 0/13 | 0/8 | 1/1 | 0/1 | 0/2 |
| DyspepsiaGastrointestinal disorders | 0/17 | 0/3 | 0/13 | 0/8 | 1/1 | 0/1 | 0/2 |
| Injection site discolourationGeneral disorders | 0/17 | 0/3 | 1/13 | 1/8 | 1/1 | 0/1 | 0/2 |
| Injection site indurationGeneral disorders | 0/17 | 0/3 | 0/13 | 0/8 | 1/1 | 0/1 | 0/2 |
| CoughRespiratory, thoracic and mediastinal disorders | 0/17 | 0/3 | 2/13 | 0/8 | 1/1 | 0/1 | 0/2 |
The safety population included all enrolled participants who received at least 1 dose in the open-label extension (OLE) study.
| Age, Continuous(years) | HAE-1/HAE-2 | HAE-nC1-INH | Total |
|---|---|---|---|
| Mean | 38.9 ± 14.68 | 34.3 ± 8.33 | 38.3 ± 13.84 |
| Sex: Female, Male(Participants) | HAE-1/HAE-2 | HAE-nC1-INH | Total |
|---|---|---|---|
| Female | 11 | 3 | 14 |
| Male | 6 | 0 | 6 |
| Ethnicity (NIH/OMB)(Participants) | HAE-1/HAE-2 | HAE-nC1-INH | Total |
|---|---|---|---|
| Hispanic or Latino | 1 | 0 | 1 |
| Not Hispanic or Latino | 16 | 3 | 19 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | HAE-1/HAE-2 | HAE-nC1-INH | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 1 | 0 | 1 |
| White | 16 | 3 | 19 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Ionis may share anonymized individual participant data, aggregated clinical data, and other types of data that support the results in this study. Data requests from qualified researchers will be considered once all three of the following criteria are met: (1) 12 months from marketing approval of the study drug in both the United States and European Union; (2) 18 months from conclusion of the study; and (3) 6 months from publication of study article. Access would be via a secure environment and is contingent upon approval of a research proposal and entry into an appropriate data use agreement. Requests to access data can be submitted via the website https://vivli.org/ourmember/ionis/.
Data sharing details ↗ · vivli.org
Ran from Mar 2020 to primary completion in Jan 2025, 57 months.
Results were first posted in May 2026, 1 year 3 months after primary completion. A results delay was requested in Jan 2026.
Of 17 phase 2 interventional studies under Angioedemas, Hereditary, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 35. This study's 57 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Donidalorsen